Chronic, destructive, mucocutaneous phycomycosis in man

Vignale, Raúl; Mackinnon, J. E.; Vilaboa, E. Casella de; Burgoa, F.

doi:10.1080/00362176485190211

Cited by 23 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shallow ulcerations have also been described (490). Some patients have demonstrated chronic infections that persisted for months or years (477,490).…”

Section: Mucor Speciesmentioning

confidence: 99%

“…There are notable cases of zygomycosis being cured by surgery only (77,373,455,462). Similarly, antifungal therapy alone has been used successfully when surgical intervention is not possible or not preferable due to the site of the infection (159,272,293,324,357,372,477,498). The vast majority of cases where successful treatment has been administered link aggressive surgical intervention with antifungal therapy and rigorous medical management of the patient.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Zygomycetes in Human Disease

Ribes¹,

Vanover-Sams²,

Baker³

2000

Clinical Microbiology Reviews

1,090

1,053

View full text Add to dashboard Cite

“…Shallow ulcerations have also been described (490). Some patients have demonstrated chronic infections that persisted for months or years (477,490).…”

Section: Mucor Speciesmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Zygomycetes in Human Disease

Ribes¹,

Vanover-Sams²,

Baker³

2000

Clinical Microbiology Reviews

1,090

1,053

View full text Add to dashboard Cite

“…There have been a few reports of chronic presentations of rhinocerebral mucormycosis, in which symptoms are indolent and slowly progressive and patients are not acutely or seriously ill 4‐16 . In such cases, tissue biopsy or culture yielded invasive mucormycosis, which was unexpected and seemingly inconsistent with the disease presentation.…”

Section: Introductionmentioning

confidence: 99%

Chronic Rhinocerebral Mucormycosis

et al. 1996

View full text Add to dashboard Cite

Rhinocerebral mucormycosis is a well-described fulminant fungal infection that typically presents acutely in patients with diabetic ketoacidosis or immunosuppression. Chronic presentations of rhinocerebral mucormycosis have also been described. In the chronic infection, the disease course is indolent and slowly progressive, often occurring over weeks to months. The authors report 2 cases of chronic rhinocerebral mucormycosis (CRM) treated at their institution and review 16 other cases reported in the English-language literature. In these cases, the median time from symptom onset to diagnosis was 7 months. The most common presenting features of CRM are ophthalmologic and include ptosis, proptosis, visual loss, and ophthalmoplegia. CRM occurs predominantly in patients with diabetes and ketoacidosis. The incidence of internal carotid artery and cavernous sinus thrombosis is higher in CRM patients than in those with the acute disease, although the overall survival rate for CRM patients is 83%. CRM is clinically distinct from chronic Entomophthorales infection.

show abstract

“…Both MCZ and CLZ are commonly used topical agents against Candi da skin or cutaneous infections. In two of the four reported cases of infection with M. ramo sissimus, the clinical manifestation was in the form of cutaneous mucormycosis [2,3]. In such cases, it may be of interest to investigate the effectiveness of these topical agents in combination with systemic AMB.…”

Section: Discussionmentioning

confidence: 99%

“…Members of this class cause progressive, necrotic and generally fatal infec tions (zygomycosis) in compromised hosts [1 ] So far there have only been four reported cases of infections caused by M. ramosissi mus: two were destructive mucocutaneous [2,3], one rhinocerebral [4], and one cerebral associated with disseminated septic arthritis [5], All four patients were immunocompro mised. No information is available pertaining to the in vitro susceptibility of this rare patho gen to antimycotics.…”

Section: Introductionmentioning

confidence: 99%

In vitro Susceptibility of <i>Mucor ramosissimus </i>Samutsevitsch, a Rare Fungal Pathogen, to Antimycotics

Sharma

Sekhon²,

Premachandra³

1995

Chemotherapy

View full text Add to dashboard Cite

The in vitro susceptibility of a rare fungal pathogen, Mucor ramosissimus Samutsevitsch, to antimycotics in clinical use was determined. Minimal inhibitory concentrations (MICs) and minimal fungicidal concentrations (MFCs) were (MIC/MFC, μg/ml): amphotericin B, 3.125/25; miconazole, 6.25/ 6.25; clotrimazole, 25/25; fluconazole, 5-fluorocytosine, itraconazole, and ketoconazole, ≥100/100. Our results show that amphotericin B and miconazole are the most effective antimycotics.

show abstract

Chronic, destructive, mucocutaneous phycomycosis in man

Cited by 23 publications

References 8 publications

Zygomycetes in Human Disease

Zygomycetes in Human Disease

Chronic Rhinocerebral Mucormycosis

In vitro Susceptibility of <i>Mucor ramosissimus </i>Samutsevitsch, a Rare Fungal Pathogen, to Antimycotics

Contact Info

Product

Resources

About